WO2010129541A1 - Sélection d'anticorps dans des émulsions - Google Patents

Sélection d'anticorps dans des émulsions Download PDF

Info

Publication number
WO2010129541A1
WO2010129541A1 PCT/US2010/033537 US2010033537W WO2010129541A1 WO 2010129541 A1 WO2010129541 A1 WO 2010129541A1 US 2010033537 W US2010033537 W US 2010033537W WO 2010129541 A1 WO2010129541 A1 WO 2010129541A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
cells
cell
protein
molecules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2010/033537
Other languages
English (en)
Inventor
Michael P. Weiner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AFFOMIX CORP
Original Assignee
AFFOMIX CORP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AFFOMIX CORP filed Critical AFFOMIX CORP
Publication of WO2010129541A1 publication Critical patent/WO2010129541A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Definitions

  • This invention is related to the area of antibodies. In particular, it relates to methods for identifying and obtaining desirable antibodies.
  • nucleic acid measurements provide useful information and these aspects have been comprehensively studied in efforts to better understand cellular events.
  • proteins not nucleic acids, carry out key metabolic processes and since the relationship between the levels of an mRNA and the protein it encodes is inconsistent at best, there is a need to directly measure proteins accurately and comprehensively as well.
  • a considerable proportion of proteins in the proteome undergo posttranslational modification (post translational modification) and neither DNA nor RNA analysis provides any information regarding the extent of such modification. This creates a substantial gap in our effort to understand cellular behavior because post translational modification is known to be extensively involved in regulatory processes.
  • Affinity reagents and in particular antibodies (Abs) are molecular tools that greatly expand our ability to characterize and study proteins, both qualitatively and quantitatively.
  • Antibodies allow researchers to identify, track, capture, quantify, control and image individual proteins.
  • antibodies should detect protein levels with a linear dose response, preferably at a range as low as 20—200 pg/ml, but also quantitatively at higher levels and with an extensive dynamic range.
  • the antibodies employed should display strong and specific signals. Ideally, the antibodies would be recombinant to enable maximum molecular biological manipulation.
  • assays typically enzyme-linked
  • affinity reagents e.g., receptors for measuring ligands and vice versa
  • they typically have neither the desired sensitivity nor the dynamic range of methods that have been implemented for tracking levels of individual nucleic acids.
  • mAbs monoclonal antibodies
  • IgG antibodies are comprised of two heavy chains and two light chains. Diversity in antibody-antigen interactions is achieved through the somewhat independent interaction of six short (3-25 amino acids) variable complement-defining regions (CDRs) in the Fab portion of the Ab.
  • An Fab portion can be used as an abbreviated Ab structure, as can single chain Ab variable region fragments (scFvs), which contain the CDRs of heavy and light chains combined into a single peptide.
  • scFvs are ideally suited for molecular screening because they can be cloned and manipulated as individual peptides while retaining the ability to bind antigen with high affinity.
  • most scFvs can be converted to, and retain activity as, conventional two-chain antibodies, if desired.
  • Ml 3 is a male- specific single-stranded filamentous bacteriophage of E. coli, which infects its host via the F-pilus.
  • the phage particle Upon entry into the cell, the phage particle is stripped of coat proteins and its circular single stranded DNA molecule is converted into a double-stranded replicative fo ⁇ n (RF). Replication of this form generates about 100 double-stranded copies, from which new single-stranded DNA and phage proteins are synthesized.
  • the single-stranded DNA is packaged and phage particles are extruded from the cell in a non-lytic manner. Approximately 200-1000 mature phages are produced per cell per generation. Ml 3 does not cause cell lysis, but growth of infected cells is slowed, resulting in turbid plaques on a lawn of uninfected cells. Infection of E. coli with Ml 3 requires a suitable F+ or F'episome-containing host strain, such as TGl or XLIBlue.
  • Phage displaying desired mAbs must be separated from those displaying irrelevant mAbs so that the former can be isolated and the genes encoding the desired mAbs obtained. This is typically achieved by "biopanning," an iterative procedure in which phage displaying appropriate mAbs on their surface bind to antigen attached to the surface of a vessel, typically wells of a microtiter dish.
  • yeast display Similar limitations apply to yeast display (Boder et al., 2000). Additional disadvantages to yeast display include smaller mutagenic library sizes compared to alternative methods and differential glycosylation (and other post-translational modifications) in yeast compared to mammalian cells. It should be noted that these disadvantages have not limited the success of yeast display for a number of applications, including engineering the highest monovalent ligand-binding affinity reported to date for an engineered protein (Boder, et al. 2000).
  • Yeast two-hybrid (Y2H) assays overcome the requirement for pure antigen (since the yeast synthesize the antigen), the time-consuming iterative process used in phage display is unnecessary and selection can be multiplexed.
  • yeast do not recapitulate post translational modification as it occurs in higher mammalian cells it is not ideal for selection of mAbs that discriminate between proteins with and without post translational modifications.
  • Microfluidic approaches have a potential for convenient and rapid selection of rnAbs that will discriminate between proteins with and without post translational modifications (Weiner, PCT/US08/73839) but this technology is not readily amenable to multiplexing.
  • Emulsions are heterogeneous systems of two immiscible liquid phases with one of the phases dispersed in the other as droplets of microscopic or colloidal size (Becher, 1957; Sherman, 1968; Lissant, 1974; Lissant, 1984). Emulsions may be produced from any suitable combination of immiscible liquids.
  • the emulsion is comprised of an aqueous phase (containing sources of antibody and antigen) present as finely divided droplets (the disperse, internal or discontinuous phase) and a hydrophobic, immiscible liquid (an "oil”) as the matrix in which these droplets are suspended (the non-disperse, continuous or external phase).
  • Such emulsions are termed “water-in-oil” (W VO); they have the advantage that the aqueous phase contains all of the biochemical and biological components whereas the external phase, being hydrophobic, generally contains none and hence is inert.
  • the emulsion may be stabilized by addition of one or more surface-active agents (surfactants) which act at the water/oil interface to prevent (or at least delay) separation of the phases.
  • surfactants surface-active agents
  • Many oils and many emulsifiers can be used for the generation of W/O emulsions; one compilation lists more than 16,000 surfactants, many of which are used as emulsifying agents (Ash and Ash, 1993).
  • Suitable oils include, but are not limited to, light white mineral oil and non-ionic surfactants (Schick, 1966) such as sorbitan monooleate (Span 80; ICI) and polyoxyethylenesorbitan monooleate (Tween 80; ICI).
  • non-ionic surfactants such as sorbitan monooleate (Span 80; ICI) and polyoxyethylenesorbitan monooleate (Tween 80; ICI).
  • anionic surfactants such as sodium cholate and sodium taurocholate might also be beneficial at a concentration ⁇ 0.5% w/v. Inclusion of such surfactants can in some cases increase the expression of the genetic elements and/or the activity of the gene products. Addition of some anionic surfactants to a non- emulsified reaction mixture completely abolishes translation. During emulsification, however, the surfactant is transferred from the aqueous phase into the interface and activity is restored. Addition of an anionic surfactant to the mixtures to be emulsified
  • IVC in vitro compartmentalization
  • a method separates antibody molecules one from another.
  • An emulsion is formed comprising a first liquid and a second liquid which are immiscible.
  • the first liquid is aqueous and comprises antibody-producing cells, and an antigen attached to a solid substrate which is suspendable in the first liquid.
  • the emulsion is incubated under conditions and for a time such that the antibody-producing cells produce antibody molecules within the first liquid and the antibody molecules bind to antigen when the antibody molecules have appropriate specificity and affinity.
  • the emulsion is broken and the first liquid is collected.
  • the solid substrate attached to antigen which is bound to antibody molecules is separated from solid substrate attached to antigen which is not bound to antibody molecules and/or from antibody molecules which are not bound to solid substrate.
  • a method makes a reagent useful for detecting an interaction with an antigen.
  • An emulsion is formed comprising a first liquid and a second liquid which are immiscible.
  • the first liquid is aqueous and comprises antibody-producing cells, and a solid substrate which is suspendable in the first liquid.
  • the emulsion is incubated under conditions and for a time such that the antibody- producing cells produce antibody molecules within the first liquid and a complex is formed comprising the solid substrate and the antibody molecules.
  • a composition comprising an emulsion.
  • a first phase of the emulsion is aqueous and comprises a solid substrate and an antibody-producing cell.
  • the antibody-producing cells express a protein which strongly interacts with the solid substrate.
  • Yet another aspect of the invention is a method for making a cell which displays a secreted protein on its surface.
  • An emulsion is formed comprising a first liquid and a second liquid which- are immiscible.
  • the first liquid is aqueous and comprises a cell which produces and secretes a desired protein, and a bifunctional reagent which binds to the desired protein and to the cell.
  • the emulsion is incubated under conditions and for a time such that the cell produces and secretes the desired protein within the first liquid and the bifunctional reagent binds to the desired protein and to the cell, whereby the desired protein is bound to the cell which produces it.
  • Still another aspect of the invention is a composition comprising an emulsion.
  • a first phase of the emulsion is aqueous and comprises a cell which produces and secretes a desired protein and a bifunctional reagent which binds to the desired protein and to the cell.
  • the bifunctional reagent binds the desired protein to the cell which produced it.
  • compositions comprising a mixed population of cells which are each decorated with a plurality of molecules of a desired protein.
  • a bifunctional reagent binds the desired protein to the surface of the cell.
  • the cell contains a nucleic acid which encodes the desired protein. Different cells in the mixed population are decorated with different desired proteins.
  • Fig. 1A-1B Cloning anti-phosphotyrosine mAb PY20 as an scFv. The cloning was performed by annealing and ligating oligos Fl-IO (SEQ ID NO:9-18) with Rl-I l (SEQ ID NO: 19-29; all 80mers that overlap each other by 40 bp; Fig. IA), then amplifying that product using F_X (SEQ ID NO:7) and R X (SEQ ID NO:8) to add Xhol sites at each end.
  • the product (which encodes a protein as shown in Fig.
  • IB will be cloned into a vector containing superfolding GFP at a Sail site immediately 5' of the start codon.
  • a clone with PY20 upstream of, and in frame with GFP will be identified.
  • the PY20 scFv was designed using VH and VL sequences from Ruff-Jamison and Glenney (J. Immunology 1993) with VH 5' of VL, separated by a (Gly4Ser)3 (SEQ ID NO: 3) linker.
  • pY20-GFP scFV binds to a phosphopeptide.
  • Cell lysate from E. co//-expressing pY20-GFP was bound to magnetic beads coated with either Streptavidin (SA), Streptavidin + biotinylated Her2 Y 1222 peptide (no phosphate; SA + Y 1222), or Streptavidin + biotinylated Her2 pY1222 phosphopeptide (SA + pY1222) for 90 minutes. Beads were then washed 3 times with lysis buffer.
  • the lysate-supernatent (S), first wash (W), and bead-eluate (E) were loaded directly onto a polyacrylamide gel, subjected to electrophoresis, electroblotted and a Western performed using anti-GFP Ab.
  • pY20-GFP binds to a phosphopeptide within an emulsion.
  • Cell lysate from E. coli -expressing pY20-GFP was bound to magnetic beads coated with either Streptavidin (SA), Streptavidin + biotinylated Her2 Y1222 peptide (no phosphate; SA + Yl 222), or Streptavidin + biotinylated Her2 pY1222 phosphopeptide (SA + pY1222).
  • SA Streptavidin
  • SA + phosphate SA + Yl 222
  • SA + pY1222 Streptavidin + biotinylated Her2 pY1222 phosphopeptide
  • Emulsions were broken, and beads were then washed 3 times with lysis buffer.
  • the lysate- supernatent (S), first wash (W), and bead-eluate (E) were loaded directly onto a polyacrylamide gel, subjected to electrophoresis, electroblotted and a Western performed using anti-GFPAb.
  • Fig. 5A-5F Growth of bacteria and protein production in an emulsion.
  • the obligate aerobe B. subtilis bacteria producing cytoplasmic-bound GFP protein were encapsulated in a 30 micron emulsion and incubated overnight at 37 C.
  • Single bacteria Fig. 5A
  • Fig. 5B Single bacteria
  • Fig. 5C Single cells
  • Fig. 5D Overnight incubated droplets are examined for growth
  • Fig. 5E protease production
  • Fig. 5F growth and protease production
  • Fig. 6 Emulsion size as a function of homogenizer speed. Size distribution of the aqueous droplets formed by emulsif ⁇ cation of an in vitro transcription-translation reaction as determined by laser diffraction: the emulsions were either stirred or stirred and then homogenized for 3 min at the indicated speeds.
  • Fig. 7 Bacterial secretion in an emulsion.
  • bacteria secrete phage e.g., bacteriophage Ml 3 displaying scFv Ab fusion on gp3 protein.
  • scFv will become bound to antigen-coated bead.
  • additional beads may also be included in the droplets to compete with the antigen-coated bead for non-specific M 13 interactors.
  • Other non-limiting examples could include lambda and T7 phage.
  • Fig. 8A-8B Phage ESCape Steps: (A) M13K07 ⁇ 9 is transfected into E. coli (F', pGP9::his6, pGP3::scFv), (B) Progeny M13 are produced packaged with pGP3::scFv DNA and displaying his ⁇ fused to gp9, and an scFv fused to gp3, (C) the progeny phage will attach to a cobalt-coated bead via the strong interaction between the his ⁇ and cobalt- chelate on the bead, (D) the emulsion is broken using a surfactant, (E) labeled antigen is added, and (F) the beads are washed under varying conditions and labeled beads are sorted away from the population of beads by flow cytometry or in bulk using a tyramide amplification assay.
  • Phage and Plasmid constructs [their gene markers (and function in the phage ESCape system)] are as follows: 1) F' [F origin, Tet resistance, (the F pilus is needed for M13 phage infection)]; 2) pGP9::his6 [CloDF13 origin, spec resistance, (provides a gp9-his6 fusion complement in trans to M13K07 ⁇ 9)]; 3) M13K07 ⁇ 9 [pl5A origin, oriFl-, gp9::lacZ, kan resistance (helper phage, requires gp9 in trans to fo ⁇ n phage particles, will preferentially package oriFl+)], and; 4) pGP3-scFv [colEl origin, oriFl+, amp resistance (provides a gp3-scFv fusion complement in trans to M13K07 ⁇ 9, preferentially-packaged by the M13K07 ⁇ 9 phage)].
  • FIG. 8B Protocol for selecting mAbs by the use of emulsions and flow cytometry.
  • E. coli cells transformed with a phagemid library encoding, for example, an scFv library and an antibiotic-resistant gene
  • helper phage M13KO7
  • the infected cells are emulsified in a W/O droplet.
  • the emulsion is collected and broken.
  • the aqueous solution from the broken emulsion is (optionally) washed, and fluorescently-labeled anti-M13 Ab is added.
  • the beads within the broken emulsion are sorted by flow cytometry to collect those beads having a high-fluorescence signal.
  • the collected beads (which may be collected into one or more test-tube(s) or individually collected in, for example, one or more 96- or 384-well microtiter plates) are spread onto a lawn of E. coli such that it allows transduction of the attached phagemid into the cells, rendering them resistant to the appropriate antibiotic.
  • Fig. 9A-9B Phage growth in W/O emulsion.
  • Fig. 9A Transduction of E. coli by filtered lysates of Ml 3 after growth of M13KO7-infected, phagemid containing E. coli incubated overnight in bulk (blue) or in an emulsion (red).
  • Fig. 9B ELISA performed with phage lysates produced in bulk (blue) or in an emulsion using anti-M13 antibody.
  • Fig. 1 OA-I OB FACS analysis of coated beads. Flow analysis of Ag-coated beads pre- treated with positive-binding phage (B3) or negative-binding phage (P3) at a ratio of 90: 10 and post-treated with fluorescently-labeled anti-M13 Ab.
  • Fig. 1 Tyramide signal amplification.
  • Peroxidase converts a fluorescein-labeled tyramide substrate to a reactive intermediate that forms a second reaction to tyrosine residues in any nearby protein.
  • Fig. 12 Design of a self signal-amplifying Ml 3 phage.
  • a genetic fusion of an enzyme [in the example shown, horse radish peroxidase (HRP)] to the M13gp7 (or 9) protein is used to generate a bacteriophage with HRP activity.
  • a scFv library can be fused to the gpIII protein. Phage attach to an Ag-coated bead (in solution, or on a solid substrate) and the signal is amplified through addition of a modified tyramide moiety.
  • Fig. 13 Biotinylation of a substrate through tyramide signal amplification.
  • Peroxidase converts a biotin-labeled tyramide substrate to a reactive intermediate that forms a second reaction to tyrosine residues in any nearby protein.
  • Fig. 14 Affinity-sorting using tyramide signal amplification: generation of biotinylated beads. Beads, cells and HRP-modified, scFv-displaying phage are encapsulated in an emulsion. The droplets are incubated for a time-period sufficient to allow phage secretion and capture onto the antigen-coated bead(s). The emulsion is broken and the beads washed. The biotin-tyramide reagent is added to the beads and the biotinylation of phage-coated beads allowed to occur. Biotin-labeled tyramide substrate is turned over by peroxidase to form a reactive intermediate that forms a second reaction to tyrosine residues in any nearby protein.
  • a separating means shown is a Streptavidin-well, but one could also use, as a non-limiting example, a Streptavidin or avidin-coated magnetic bead. The beads are washed to remove non- or under-biotinylated beads and the remaining beads are plated onto a lawn of, for example, E. coli cells.
  • Fig. 16 Proposed work-flow for high-throughput mAb production using emulsions. Shown is an example using FACS sorting. The method would potentially be modified for use in another sorting means, for example, magnetic sorting.
  • Fig. 17. Yeast surface display.
  • the Aga2P gene of yeast can be genetically-modified to have fused to it a hemagglutination (HA) tag site and a means for capturing IgG molecules secreted into the droplet.
  • the capturing molecule is a staphA protein.
  • the tag site can be used to calibrate/quantify the concentration of the fusion protein to the yeast surface.
  • Other examples could include an anti-human IgG protein.
  • Fig. 18 Yeast secretion and capture within a droplet.
  • a yeast is either coated or made to genetically expose a surface moiety capable of binding an IgG or Fab molecule.
  • An IgG or Fab molecule library is transformed into yeast cells to create a yeast IgG or Fab library, respectively.
  • Cells from this library, along with a fluorescently-labeled peptide, are emulsified and incubated in the droplet. After a sufficient period of time to allow the yeast to secrete and capture the either IgG or Fab molecule, the emulsion is broken and the aqueous phase is sorted using, as a non-limiting example, flow cytometry.
  • Fig. 19A-19B Non-yeast cell secretion and capture within a droplet.
  • a non- yeast cell is either coated with, or made genetically to expose a surface moiety capable of capturing an IgG or Fab molecule.
  • An IgG or Fab molecule library is transformed into the non-yeast cells to create a IgG or Fab library.
  • Fig. 19B Cells from this library, along with a fluorescently-labeled peptide, are emulsified and incubated in the droplet.
  • B-cells are enriched from a human tissue or blood sample.
  • the B-cell is coated with a bispecific antibody consisting of anti-CD 19 antibody coupled to a goat anti-human IgG antibody.
  • the coated B-cell is emulsified along with a labeled peptide in a droplet.
  • the labeled-peptide/B-cell emulsion is incubated for a time-period sufficient to allow secretion and capture of the IgG antibody on the B-cell surface.
  • the emulsion is broken, the aqueous phase washed, and the washed cells flow sorted.
  • Fig. 20 Construction of a random peptide library. Triplet codons can be incorporated into a growing chain using synthetic codon linkers as shown.
  • Step A In the example shown, an anchor primer is attached to a solid substrate, either a bead or the surface of a solid substrate such as a 96-well microtiter plate. The substrate is used to facilitate washing of me growing chain between steps.
  • the anchor primer is a hairpin loop that contains a upstream priming site and ends in a blunt-end.
  • the anchor primer also contains a means for its removal from the substrate, for example a restriction enzyme site.
  • a codon linker is ligated to the anchor primer.
  • the codon linker consists of three specific bases (denoted by NNN) that are placed upstream of a type II restriction enzyme such as MIyI.
  • a type II restriction enzyme such as MIyI.
  • the 5' end of the codon link is phosphorylated.
  • the codon linker is constructed such that there is a hairpin-loop.
  • the number of codon linkers can be varied such that 1 to 64 possible triplet codons can be added to the growing chain.
  • a subset of the 64 triplet codons such as just the 20 that code for the unique set of amino acids, or the preferred codons used for expression in a specific organism, or codons that do not make a MIyI site (see step C).
  • a set of 20 codon linkers can be synthesized such that the first (or second) codon is "fixed”. This would also be performed if more than one amino acid can be fixed within the sequence.
  • a set of 20 codon linkers could be made with the end sequence equivalent to 5' -ATGNNTNI ATG-3 " (SEQ ID NO: 1) wherein the middle base form one of 20 amino acid codons, and the flanking ATG sequences incorporate a methionine amino acid into the protein chain.
  • codon-linkers can be added at differing or identical ratios such that there either will or will not be a skewing of which codon linkers get ligated into the growing chain. It is known that T4 DNA ligase has preferred DNA sequences for ligation. This ratio can be based on the molar mass ratio of the various codon-linkers or could be based on the relative efficiency of a particular codon linker to be ligated into the growing chain.
  • Step B To increase ligation efficiency, a crowding agent(s) such as (10-25%) polyethylene glycol may be optionally added to the ligation mix.
  • a crowding agent(s) such as (10-25%) polyethylene glycol may be optionally added to the ligation mix.
  • both the anchor and linker primers are 5' phosphorylated (either during oligonucleotide synthesis or either post-ligation or synthesis using T4 polynucleotide kinase and ATP), then exonuclease can be used to remove any unligated anchor or codon primer remaining in the reaction.
  • the ligated anchor-primer/codon-linker forms a molecules with both ends sealed (i.e., a single DNA strand without a free end).
  • Step C The restriction endonulcease MIyI makes a double-strand cut 5 bases upstream (on both strands of the DNA) of its recognition site. The restriction digested product can be washed away from the bound anchor-primer. Step D: the process is repeated (steps A-C) to add more codon linkers. Step E: When the chain has grown such that the end is reached, then a terminal linker can be attached.
  • This terminal linker can optionally incorporate aNNN sequence at its 5' end.
  • the terminal linker could also contain a downstream primer-binding site that could be used in conjunction with the anchor primer binding site to enable one to PCR or amplify the grown chain.
  • Step F The completed chain can be optionally separated from the substrate using various means, including a restriction enzyme, chaotropic agent, change in pH, organic solvent, heat, chemical or enzymatic decoupling.
  • the freed DNA fragment can be cloned directly into a vector, used for splice overlap extension, or amplified by one of many means, including PCR and rolling circle amplification.
  • Fig. 21 Cryogenic storage of phage-coated bead emulsions.
  • M13K07 helper phage and antigen-coupled beads were added to E. coli (F') containing ampicillin-resistant phagemid expressing an anti-interferon gamma scFv-gp3 fusion.
  • An emulsion was generated by subsequent addition of perfluorocarbon oil.
  • Infected cells were incubated at 30 0 C overnight for phage production.
  • Emulsions were either frozen at -80 0 C or broken. Cells were pelleted, beads were washed and frozen in the absence or presence of a cryoprotectant. Stability of phage-containing beads after freezing was examined by ELISA using anti-M13-HRP antibody.
  • FIG. 22 Schematic of Method of Phage ESCape.
  • E. coli cells transformed with a phagemid library is infected with helper phage (M13KO7 ⁇ 9 helper phage.
  • the infected bacterium is then compartmentalized along with a cobalt-chelate "capture-bead" in a water-in-oil [W/O] emulsion. Consequently, in each isolated compartment during overnight incubation, thousands of copies of the recombinant phage displaying both an scFv protein at one end (fused to the gp3 protein) and a his ⁇ peptide at the opposite end (fused to the gp9 protein) are produced.
  • the his6-end of the display phage binds to the cobalt-chelate capture-bead.
  • the emulsion is broken and these beads, along with any phage bound to them, are isolated.
  • the phage-bound beads are incubated with a fluorescein-labeled antigen and then washed to remove any excess ligand.
  • the labeled beads are then sorted (together with the phage attached to them) from the population of beads by flow cytometry. Enriched beads are plated onto a lawn of E. coli and the phagemid-encoded scFv further tested for specificity and affinity.
  • the applicants have invented emulsion-based methods for selection of antibodies.
  • the methods have applicability for multiplexing, require relatively small amounts of antigen, can be used to select for antibodies directed to post-translational modifications, and can be designed to select simultaneously on the basis of affinity and specificity.
  • it provides a convenient approach for library construction that is amenable to long-term storage.
  • the use of emulsions permits, for example, individual query of the ability of each antibody to bind to an antigen-coated solid substrate, yet the procedure is massively multiplexed, so that upwards of 10 9 individual queries can be carried out in approximately one hour.
  • the methods can be applied to a number of different sources of antibody including bacteriophages, viruses, bacteria, yeast, or higher eukaryotic cells, including hybridomas and normal immune cells, such as B cells.
  • Emulsions permit the production of solid substrates or cells which can be decorated with a single species of protein or antibody molecule. Yet the solid substrates or cells can be in a mixture such that the single species on one solid substrate or cell differs from the next. Thus a solid substrate or cell becomes an anchor for identical antibodies or proteins, thus the signal of each antibody or protein is amplified.
  • the ratio of solid substrate to antibody producing cell to emulsion compartments can be readily adapted to maximize the number of compartments with a single antibody-producing cell and one or more solid substrates.
  • At least 5 %, at least 10 %, at least 15 %, at least 20 %, at least 25 %, at least 30 %, at least 35 %, at least 40 %, at least 45 %, at least 50 % or more of the solid substrates may carry a single antibody or protein species.
  • additional amounts of the antibody can be generated using the cell which made the antibody, or using the recombinant construct to transform additional cells, or by using the bacteriophage or virus to infect additional cells.
  • the methods are particularly designed to facilitate this process by physically linking the desired antibodies to the nucleic acid sequences encoding them. This physical linkage need not be direct. In most cases there are one or more intermediaries in the linkage. For example in a cell that expresses a desired antibody or protein, the linkage to the desired antibody or protein may be made via a bifunctional reagent that binds both to the cell and to the antibody or protein.
  • a non-limiting example of a bifunctional reagent is a bifunctional antibody.
  • a cell surface may be modified either chemically or genetically to display a moiety on its surface through which a cell may be attached to an antibody or other protein.
  • a cell may express a protein on its cell surface or on the surface of a virus or bacteriophage that binds strongly to a moiety on the solid substrate.
  • Labeling of antibodies may similarly be accomplished directly or indirectly.
  • An example of indirect labeling is the binding of a labeled goat anti-human antibody to a human antibody.
  • a non-limiting example of direct labeling is the use of a genetic fusion construct between an antibody molecule and a green fluorescent moiety.
  • Separating, detecting, and analyzing solid supports or cells bound to antibodies can be accomplished by any means known in the art. Two useful means are flow cytometry and flow sorting. Separations can also be accomplished by means of centrifugation, by means of magnetic attraction of paramagnetic particles, and by affinity attraction. In some cases it may be useful that the solid substrate itself be detectably labeled.
  • a cell, virus, or bacteriophage encoding a desirable antibody molecule can be cultured to achieve a larger stock of the antibody, cell, virus, or bacteriophage. The culturing may be used to achieve a sufficient amount of nucleic acids to conveniently sequence the antibody-encoding nucleic acid species.
  • a solid substrate is complexed with antibodies, wherein in others, the solid substrate is complexed with antigens.
  • the reagents are useful for detecting binding between antibodies and antigens and for recovery of the nucleic acids encoding the antibodies.
  • Either antigens or antibodies may be physically complexed with the solid substrate, usually through intermediate binding moieties.
  • a solid substrate can be coated with nickel or cobalt ions and these can be used to bind his-tagged proteins or antibodies to the solid support. Other binding pairs can be used to link a protein or antibody to the solid support, such as using avidin or streptavidin and biotin.
  • Competing species may be introduced into binding reactions in order to increase the stringency of detected binders.
  • Species which may be used include without limitation, solid substrates with no attached proteins, soluble proteins which may be similar to an antigen of interest, and soluble proteins which are not similar to an antigen of interest.
  • the technology is useful inter alia for detecting an interaction between an antigen and a mAb.
  • the antigen may be a protein, a polypeptide, a peptide, a protein carrying a post- translational modification including but not limited to phosphorylation, glycosylation, sialylation and the like, or even a non-peptidic molecule.
  • the mAb may be a conventional IgG, a Fab fragment or a scFv. Each of these antibody or antibody-like structures is referred to here genetically as a mAb.
  • the mAb may be a hybrid protein comprising, variously, a conventional IgG, a Fab fragment or a scFv fused to a polypeptide.
  • the polypeptide fusion partner may have properties that influence the location of the mAb ⁇ e.g., on the external surface of a cell or a vims or secreted into the milieu) and/or enhance the ability of the mAb to be detected and/or facilitate purification of the mAb.
  • Non-limiting examples of such polypeptides are surface structural polypeptides of cells, bacteriophage or viruses; enzymes, including, without limitation, alkaline phosphatase, halogenase or horseradish peroxidase (HRP), ligands that bind tightly to cell surface receptors or polypeptides that can readily be detected by fluorimetry or colorimetry, including, without limitation, green fluorescence protein (GFP).
  • the hybrid protein comprises a multiplicity of polypeptides that influence mAb location and/or enhance the ability of the mAb to be detected and/or facilitate purification of the mAb.
  • Each mAb can be synthesized within a host cell.
  • the host cell may variously be a recombinant bacterial cell, a bacterial cell infected with a bacteriophage, a recombinant yeast cell, a recombinant higher eukaryotic cell, a eukaryotic higher cell infected with a vims, a hybridoma or a mammalian immune cell that is programmed to express one or more of its endogenous Ab genes.
  • One or more Ab genes may be introduced recombinantly into the genome of a host cell.
  • the host cell may be a bacterium and one or more Ab genes may be introduced into the bacterium recombinantly.
  • the host cell may be a bacterium and one or more Ab genes may be introduced into the bacterium via a bacteriophage.
  • the host cell may be a eukaryotic cell and one or more Ab genes may be introduced into the cell recombinantly.
  • the host cell may be a eukaiyotic cell and one or more Ab genes in the cell is introduced into the cell via a virus.
  • the host cell may be an antibody-producing cell that had been obtained from or derived from the immune system of a mammal.
  • the mammalian source of the immune cell may optionally be human.
  • the host cell may also be a hybridoma of either human or non-human origin.
  • Bacterial host cells can be recombinantly manipulated so that as a population they collectively express a library of mAbs.
  • the bacteria may express mAbs on their surface.
  • the bacteria may be infected with a population of bacteriophage that has been recombinantly manipulated so as to express on their surfaces a library of mAbs.
  • the bacteriophage may be released from the host bacteria into the medium.
  • Eukaiyotic cells may be recombinantly manipulated so that as a population they collectively express a library of mAbs.
  • the eukaryotic cells may express mAbs on their surface.
  • the mAbs may be secreted into the medium and captured by a molecule located on the eukaryotic host cell surface.
  • the cells may be genetically modified to produce Staph A protein on their surfaces, the mAbs produced by the cells may be IgG molecules which, following secretion, may be captured by the surface Staph A protein.
  • the antibody-producing cells may be hybridoma cells.
  • Eukaryotic cells can be infected with a virus recombinantly manipulated so that as a population they collectively express a library of mAbs.
  • each mAb is part of a fusion protein that additionally contains an epitope that binds to a receptor on the surface of the host cell.
  • the eukaryotic cells express mAbs on their surface.
  • virus expressing mAbs on their surface are released from the host cells into the medium.
  • An antigen may be attached to a solid substrate that can optionally be suspended in an emulsion.
  • the solid substrate may be a bead, microsphere, particle etc. that is relatively inert.
  • One bead that is of suitable size for use in emulsions is a 5-micron bead.
  • Another suitable solid substrate is a magnetic bead.
  • the solid substrate may be suitably marked so that it can be tracked by a fluorimetric or colorimetric detector.
  • the marker may be on the surface or internal to the bead, microsphere, or particle.
  • the antigen may be modified so that when it is attached to the solid substrate, the solid substrate can be tracked by a fluorimetric or colorimetric detector. Both or either of the solid substrate and the antigen may be so marked, so that they can be differentially or additively tracked by a fluorimetric or colorimetric detector.
  • Antibodies may be selected on the basis of specificity as well as affinity.
  • a non-target molecule can be added to the medium at a concentration such that if a mAb is non-specific it is sequestered in the medium by interaction with the non-target molecule such that binding sites on the mAb will not be available for interaction with the targeted Ag.
  • antigen can be selected on the basis of specificity by being bound to a first bead that can be distinguished from a second bead to which the desired target antigen is not bound.
  • the source of mAb (whether cells, phage, or virus) can be mixed with antigen attached to an appropriate solid substrate (e.g., a bead) in a suitable first liquid and an emulsion of that first liquid can be created in an appropriately immiscible second liquid.
  • the first liquid is an aqueous medium and the second liquid is a hydrophobic liquid, such as, an oil. Any two immiscible liquids known in the art may be used, so long as the first liquid can sustain cell growth and optionally virus or phage production.
  • the emulsion can be created by manual mixing of the first and second liquids.
  • the emulsion can be created by a device that generates an emulsion in which droplets are relatively uniform in size. Emulsions may alternatively be made in a device possessing a series of nozzles so that emulsions are effectively produced in a multiplexed fashion. Any means known in the art for making emulsions may be used.
  • the emulsion can be broken by any means known in the art. Centrifugation and/or addition of a suitable agent or mixture of agents, such as a detergent or mixture of detergents, can be used to break the emulsions.
  • a suitable agent or mixture of agents such as a detergent or mixture of detergents.
  • the first liquid from the combined droplets within the emulsions are collected and pooled. After collection and pooling, the first liquid can be subjected to a separation procedure that stratifies phage or virus or cells that are bound to one or more beads containing antigen.
  • One such stratification procedure which may be used is by flow cytometry. Fluorescence activated cell sorting may alternatively be used. Bacteriophage or virus or cell that is attached to one or more antigen-containing solid substrates may be recovered and used to produce more of the mAb which has been selected. The bacteriophage or virus or cell may be used as a source of genetic material for sequencing of the mAb-encoding gene(s).
  • the emulsions can be used for creating libraries of antibodies attached to a solid substrate, without the presence of antigen.
  • the solid substrate may be coated with a binding partner for antibodies, with a binding partner for a fusion partner of the antibodies (if made as a fusion protein), or for the bacteriophage producing the antibodies on their surfaces or for the cells expressing the antibodies on their surfaces.
  • the solid substrate from a single emulsion droplet would be homogeneously decorated with a single antibody member of the library. Different solid substrates within the population would be decorated with different library members.
  • the libraries of antibodies attached to the solid substrates can be stored before further use, either as an emulsion or as the first liquid phase of the broken emulsion.
  • cryoprotective substances can be added to enhance the shelf-life of the libraries.
  • suitable cryoprotective substances include those which increase the osmolality of the medium, such as glycerol, mannitol, sucrose.
  • target antigen can be added to aliquots of the library of antibodies on solid substrates. After a suitable period to allow appropriate antigen- antibody interaction to occur, the mixture can be subjected to a separation procedure, e.g., that stratifies Ag-mAb-solid substrate complexes from complexes that do not contain antigen.
  • HER2 human is a proto-oncogenic receptor tyrosine kinase of the EGFR family.
  • a phosphorylated peptide of Her2_Y1222 has the sequence PAFDNLYp YWDQDPPE (SEQ ID NO: 2). This sequence is used as a target epitope in the Example.
  • Fig. 3B The sequence of the PY20 peptide is shown in Fig. 3B.
  • a his ⁇ tag was fused to the construct for use in protein purification.
  • a (Gly4Ser)3 (SEQ ID NO: 3) linker at the 3' end was also added to allow fusion to another protein.
  • the amino acid sequence was reverse-translated and the codons were optimized for expression in E. coli.
  • Splice overlap PCR was used to generate the full-length gene fragment.
  • the synthetic gene was cloned into a pET vector under the control of a T7 promoter. DNA sequencing was performed to identify a clone with the correct sequence.
  • Bacteria and bacteriophage can survive the emulsion process. Bacteria have survived compartmentalization for up to several days in the perfluorocarbon oils we are using for making our emulsions (e.g., Fig. 7). We have also determined that E. coli produced M13KO7 helper phage when incubated overnight in oil droplets and survived for at least six days thereafter.
  • the method for attachment is EDC-based direct chemical coupling to derivatized 5.6 ⁇ m beads through an activated amine group on the peptide.
  • Biotin-coupled peptides are attached to streptavidin-coated beads.
  • the phosphorylated peptide (Her2jpY1222; Cell Signaling, Inc. (Beverly, MA) is attached to one set of beads; the same peptide absent the phosphotyrosine (Her2_Y1222) is attached to a fluorescently-distinguishable set of beads and used as a negative control.
  • the commercially-available murine IgG anti-phosphotyrosine hybridoma CRL-1955 from ATCC Manassas, VA
  • Fluorescein is attached to the Luminex and streptavidin beads at several calibrated concentrations. These fluorescein- bound control beads are used to determine and optimize detection and differentiation of the background and fluorescein-generated signal.
  • Recombinant Ml 3 bacteriophage We have obtained 10 different scFvs against two peptide epitopes of IFN ⁇ by biopanning, 6 different scFv mAbs against the IFN ⁇ _3 peptide that recognize both the peptide and full-length protein and 4 different scFv mAbs against the lFN ⁇ _4 peptide that recognize both the peptide and full-length protein.
  • a 3+3 phasmid system is used based on pBlueScript and which can rescue the phasmid with M13KO7 helper phage using published protocols.
  • PY20 scFv is sub-cloned from the scFv-GFP fusion (see Example 1) into this plasmid system.
  • a Luminex 100 IS (Austin, TX) xMap instrument is used to analyze and decode at least two different Luminex-type beads and fluorescein dye intensities on a bead as a model for flow cytometry studies.
  • the Luminex machine uses a 532 nm green laser to excite a reporter molecule (phycoerythrin, Cy3, etc.) and a 635 nm diode laser to excite the red and near infrared fluorescence from the dyes used to color-code the beads.
  • Fluorescein dye and antibodies are purchased from Invitrogen, Carlsbad, CA.
  • a flow cytometer may be used to sort the beads.
  • any of the following high-speed sorters can be used: a BD FACS Vantage SE, a BD Aria, and a Dako MoFIo.
  • Cells are sorted at rates of up to 20K/sec. at 99+% purity, using a variety of commonly used fluorochromes, including but not limited to FITC, PE, PE-Cy5, APC, APC-CY7, PE-CY7, CY5, Alexa680 and PI.
  • the MoFIo has 7- color
  • Vantage SE has 6-color
  • the Aria has 10-color capability.
  • Cells are sorted into 5 or 15 ml tubes or into various plates as single or multiple cells/well or onto microscope slides for analysis.
  • the sorters are capable of simultaneous 4-way sorting.
  • FACS Vantage SE and FACS Aria are also equipped with aerosol management systems making them suitable for sorting live human, primate or other potentially biohazardous cells.
  • Flow-sorting technology can process nearly 1 billion beads per hour, in a total volume of less than 1 ml.
  • We and others (Sepp 2002) have shown that we can detect increased fluorescence signal on a bead.
  • Spiking experiments i.e., adding a phage expressing an mAb that binds to a bead in the presence of an excess of non-binding phage
  • Emulsions are prepared using variations of the procedure described in Example 6 to vary the size of the emulsion droplets, phage and bacterial titers and concentration of beads.
  • 950 ⁇ L of an oil-surfactant mixture [Span 80 2.25 ml 4.5% (wt/wt) Tween 80 250 ⁇ l 0.5% (wt/wt), Mineral oil to 50 ml) is cooled on ice along with a 3x8 mm stir bar. The mixture is stirred at 1,150 r.p.m. on a magnetic stirrer with a tube supported in an aluminum block pre-cooled on ice (or in a beaker containing ice water). The aqueous phase is added gradually to the oil-surfactant mixture as 5 aliquots of 10 ⁇ l over a period of 2 min.
  • an oil-surfactant mixture [Span 80 2.25 ml 4.5% (wt/wt) Tween 80 250 ⁇ l 0.5% (wt/wt), Mineral oil to 50 ml) is cooled on ice along with a 3x8 mm stir bar. The mixture is stirred at 1,150 r.p.m. on a magnetic stirrer with a
  • the reactions are quenched when the emulsion is broken by spinning at 3,000 xg for 5 minutes and removing the oil phase, leaving the concentrated emulsion at the bottom of the vial.
  • the size distribution of the aqueous droplets in the emulsions can be determined by laser diffraction using a Coulter LS230 Particle Size Analyzer. An aliquot of emulsion, freshly diluted (1 :10) in mineral oil is added to the micro-volume chamber containing stirred mineral oil. Results are analyzed with the instrument's built-in Mie optical model using refractive indices of 1.468 for mineral oil and 1.350 for the aqueous phase.
  • the infected cells are resuspended in Luria-Bertani (LB) medium containing a predetermined number of Ag- coated beads.
  • the concentration (and number) of beads are estimated using a hemocytomer.
  • the number of viable cells is estimated by absorbance at 600 run (A600) and (prior) calibration of A600 to colony-fo ⁇ ning units on agar plates.
  • the ratio of cells :beads and total concentration of cells and beads are varied in the LB medium.
  • the aqueous medium is emulsified as described above.
  • the size of the microdroplets is varied.
  • the emulsion is incubated for up to 24 hours, with portions removed at appropriate (e.g., 2 hr) intervals.
  • the phage multiply within the aqueous droplets within the emulsions (Fig. 9A and 9B).
  • the emulsions are broken as described above and the number of transducing phage particles in the aque
  • the antigen under investigation i.e., the phosphotyrosine-encoding peptide Yl 222
  • a second bead type is either 'naked' (i.e., nothing attached to the bead) or is conjugated with at least one of either non- phosphorylated peptide, or BSA.
  • the PY20 antibody is used as a first test mAb.
  • the beads are blocked with BSA or powdered milk prior to use. It is noted that the amount of time that encapsulated bacteria need to be incubated to express sufficient scFv-M13 for detection is an important aspect of this specific aim. It is assumed that 6-12 hours will be sufficient, but this number is determined empirically for the various emulsions.
  • FIG. 10 provides an example of how coated beads are sorted by flow cytometry. Aliquots from the above set of experiments are also used to determine the correlation between flow-cytometry sensitivity, plaque-forming units, ELISA results and the number of transducing phage particles. Flow cytometry is carried out as described in Example 5. This step provides guidance for calibration of results in future experiments. Transducing phage are resuspended on single beads, collected and scFv-specific primers are used to validate the percent homogeneity of bound phage on each particle.
  • washing temperature is varied: washes are performed either on ice or at room temperature. Conditions are defined that reduce or eliminate non-specific mAb binding within a sorted emulsion to less than 5%.
  • Test wash conditions as a function of Kd for IFN ⁇ phage To test if Kd can be calibrated by wash conditions, 109 different phage carrying mAbs against IFN ⁇ are tested in separate compartments via formation of an emulsion. A 3+3 phagemid system, which is considered to generate 99% of the particles with 0 gpIII-scFv fusions and approximately 1 % of phage having 1 gpIII-scFv fusion product on the phage particle is used for these experiments in order to reduce avidity effects. It is determined under conditions of saturation of the beads in each compartment with phage whether making the wash conditions progressively more stringent leads to isolation of phage having greater affinity for antigen on the beads.
  • This potential correlation between wash stringency and mAb affinity is evaluated by determining whether there is a correlation between fluorescence signal on the bead with affinity.
  • IFN ⁇ scFvs selected by these procedures are analyzed by Biacore analysis to determine their Kds and a curve of fluorescence vs Kd for each of the various wash conditions is generated.
  • the objective of this example is to prepare a large, quality-controlled na ⁇ ve phage library that carries a scFv framework that is functional in an emulsion system in the presence of E. coli.
  • the distal end of the phage is constructed to carry an enzyme system that will increase efficiency of selection of desired mAbs.
  • na ⁇ ve bacterial phage library for the emulsion screen has several advantages, including reduced costs, system simplification, less dependence on vertebrate animals, better cell recovery and increased ease of handling.
  • Tyramide is a phenolic compound that, when activated by the enzyme horseradish peroxidase (HRP), covalently binds to electron rich moieties on a surface (i.e., predominantly to tyrosine residues in proteins).
  • Tyramide Signal Amplification (Fig. 11) is based upon derivatized tyramide.
  • immobilized HRP converts the labeled substrate (tyramide) into a short-lived, extremely reactive intermediate.
  • the activated substrate molecules then very rapidly react with and covalently bind to electron-rich regions of adjacent proteins. This binding of the activated tyramide molecules occurs only immediately adjacent to the sites at which the activating HRP enzyme is bound.
  • tyramide-fluorescein can be used with tyramide-fluorescein to significantly increase signal on the phage-bound bead.
  • approximately 2,700 copies of gp8 are modified to encode extra tyrosine residues on the phage surface.
  • Figs. 12 and 13 illustrate examples of the use of tyramide substrate to amplify signal when phage carrying scFvs bind to bead coated with cognate Ag.
  • Fig. 14 illustrates a non-limiting procedure for generating phage:bead complexes in which signal has been amplified with tyramide.
  • Fig. 15 illustrates a non-limiting procedure for recovering phageibead complexes in which signal has been amplified with tyramide.
  • the same library construction method used to synthesize a yeast scFv library can be used for E. coli.
  • a scFv framework is chosen that enables efficient expression in the bacterium and functions with appropriate characteristics in an emulsion once secreted. In order to prevent the biased outgrowth of a limited number of clones, all growth of the transformants take place on a solid agar medium. Ml 3 phage and host E coli can survive in emulsion droplets for at least 2 days and can secrete active phage particles into the medium.
  • a framework is chosen that enables functionality in our emulsions.
  • Example 9 Functional Subtraction of Libraries to remove mAbs with non-specific binding properties.
  • mAb libraries are initially functionally subtracted to eliminate non-specific interactors by flow-sorting the entire library against beads carrying a non-target molecule and thereby removing any library members that either specifically bind to that molecule, or non- specif ⁇ cally bind to that molecule or anything else on the bead.
  • Functional subtraction is carried out on libraries in bacteria, yeast, other eukaryotic cells, phage or viruses, provided that they surface display the mAb.
  • the source of the mAb library be they bacteria eukaryotic cells, phage or vims, are screened for binding to a one or more non- target molecule(s) covalently attached to a bead.
  • Luminex beads are used in this procedure; they contain bound non-target molecule(s) and are also labeled with a fluorescent dye molecule. After incubation for sufficient time to allow binding to occur, the solution is injected into a flow cytometer. Beads (with attached mAbs) are sorted out of the mixture and discarded; non-binding library members are collected. This procedure is reiterated as necessary until few or no library members bind to beads. The remaining library members are expanded and become the source of the "functionally-subtracted" library.
  • E. coli infected with a library of phage M 13 encoding scFv variants are compartmentalized with Ag-coated beads in a W/O emulsion to give, on average, ⁇ 1 bead and 1-10 infected bacteria per compartment.
  • the library is prepared as described in Example 8 (as an option, the gp7- or gp9-modif ⁇ ed library described in Example 8 is used). In each compartment, multiple copies of the recombinant phage are produced, some of which may bind to the Ag-coated bead.
  • the emulsion is broken and the microbeads, along with bound phage, are isolated.
  • the beads are incubated with ligand or anti-M13 IgG Ab coupled to HRP (see Example 8), washed to remove unbound ligand or mAb, and incubated with hydrogen peroxide and fluorescein tyramide.
  • Immobilized HRP converts the fluorescein tyramide into a short-lived, free-radical intermediate which reacts with adjacent proteins.
  • beads coated with Ml 3 phage that bind to the Ag-coated beads become labeled with multiple fluorescein molecules. These beads are then enriched (together with the phage attached to them) by flow cytometry.
  • the [bacteria + Ag-coated beads] emulsion is generated and collected for incubation in a syringe. After incubation at 37°C for sufficient time to allow phage production and binding of mAb to Ag-bead, the emulsion is broken, the beads separated and the washed beads are injected into a flow cytometer and subjected to sorting. Individual beads flow past a laser detector for fluorescence analysis. Based on this real-time analysis, a decision is made whether an individual bead has a fluorescent signal coincident with the bead above a chosen threshold (e.g., 3x above background). Droplets with signals above the threshold trigger voltage generation in the sorting electrode which causes the droplet to move into the "keep" channel. Beads with signals below the threshold flow into the waste channel.
  • a chosen threshold e.g., 3x above background
  • the sorted phage are recovered and plated on agar along with a bacterium capable of infection by the phage: the beads from the "keep" channel are spotted in the center of the plate, and mechanically dispersed using a sterile glass spreader.
  • the resulting transduced bacteria after overnight incubation, are grown in LB liquid medium and transduced using M13KO7 helper phage for scFv-M13 production. These phage particles are subsequently tested by standard ELISA format for binding to both phosphorylated and non-phosphorylated Yl 222 peptide.
  • non-phosphorylated Her2_pY1222 peptide is added to the medium prior to formation of the emulsion at a concentration such that phage and beads are incubated together in the presence of an excess of non-target peptide. Accordingly, the preponderance of phage that bind to beads have a higher affinity for the phosphorylated peptide (target) than for the non-phosphorylated (non-target) version of the peptide.
  • coli and helper phage are added to the wells and the plate incubated overnight. Clones are streaked for single-colony transductants and the colonies are expanded as a source of mAb fro purification and analysis.
  • an aliquot of recombinant phage [displaying the encoded scFv] is added to wells containing a Luminex bead coated with the original antigen + 7 different Luminex beads, each coated with a different antigen. Labeled anti-M13 antibody is added to these wells and subjected to Luminex multiplex and the mAb gene is characterized by DNA sequencing (Fig. 16).
  • Example 13 A high throughput approach for selecting mAbs by the use of emulsions and yeast display.
  • yeast cells are genetically altered so as to express and secrete a library of IgG genes as well as to express and display on their surface a recombinant fusion protein containing the Aga2P gene of yeast-hemagglutinin (HA) site- staph A protein.
  • the expressed protein is anchored to the surface of yeast cells via interaction of the Aga2P moiety to AgalP (Fig. 17).
  • Emulsions are formed as in the examples described above and mAbs secreted in the droplet bind to the surface of the mAb-secreting yeast.
  • Also present in the droplets are beads carrying target antigen linked to a fluorescent moiety. Yeast with adherent mAb that binds to the antigen on the bead thus bind to the fluorescent beads. The emulsion is broken and yeast associated with fluorescent beads are sorted (Fig. 18).
  • FIG. 19A-19B illustrates the procedure.
  • the cells alternatively express IgG endogenously (e.g., hybridoma cells) or an IgG library is transformed into the cells.
  • the cells are either coated with, or made genetically to expose, a surface moiety capable of capturing an IgG molecule.
  • the cells are genetically manipulated to express Staph A protein on their surface.
  • the cells along with a fluorescently-labeled antigen, are emulsified and incubated in the droplet in the presence of medium such that if serum-containing medium is used, the serum has been depleted of exogenous immunoglobulin. After a sufficient period of time to allow the cells to secrete and capture the IgG molecule, the emulsion is broken and the aqueous phase is sorted using, as a non-limiting example, flow cytometry, to capture fluorescently-labeled cells.
  • Example 15 In this example a mAb library, alternatively scFv or Fab or IgG, is transformed into non- yeast eukaryotic host cells.
  • the mAbs are each part of a fusion protein together with a ligand that binds to a surface receptor on the host cell. Any of a large number of ligand:receptor pairs known in the art is used.
  • the host cell is emulsified along with a labeled antigen in a droplet.
  • the labeled Ag-host cell emulsion is incubated for a time- period sufficient to allow secretion and capture of the recombinant mAb-ligand fusion protein on the host cell surface.
  • the emulsion is broken, the cells are washed, the washed cells flow sorted and fluorescent cells are collected.
  • Example 10 The procedure in Example 10 is alternatively carried out such that the aqueous phase in the emulsion also contains one or more non-target molecules as described in Example 1 1 , such that the mAb attached to the cells preferentially binds the target antigen as opposed to the non-target molecules in the aqueous solution.
  • an anchor primer is attached to a solid substrate, either a bead or the surface of a solid substrate such as a 96-well microtiter plate.
  • the substrate is used to facilitate washing of the growing chain between steps.
  • the anchor primer is a hairpin loop that contains a upstream priming site and ends in a blunt-end.
  • the anchor primer also contains a means for its removal from the substrate, for example a restriction enzyme site.
  • a codon linker is ligated to the anchor primer.
  • the codon linker consists of three specific bases (denoted by BBB) that are placed upstream of a type II restriction enzyme such as MIyI.
  • a type II restriction enzyme such as MIyI.
  • the 5' end of the codon linker is phosphorylated.
  • the codon linker is constructed such that there is a hairpin-loop.
  • the number of codon linkers can be varied such that 1 to 64 possible triplet codons can be added to the growing chain.
  • a subset of the 64 triplet codons such as just the 20 that code for the unique set of amino acids, or the preferred codons used for expression in a specific organism, or codons that do not make a MIyI site (see step C).
  • a set of 20 codon linkers can be synthesized such that the first (or second) codon is "fixed”. This would also be performed if more than one amino acid can be fixed within the sequence.
  • a set of 20 codon linkers could be made with the end sequence equivalent to 5' -ATGNNNATG- 3' (SEQ ID NO: 1) wherein the middle bases form one of 20 amino acid codons, and the flanking ATG sequences incorporate a methionine amino acid into the protein chain.
  • codon-linkers can be added at differing or identical ratios such that there either will or will not be a skewing of which codon linkers get ligated into the growing chain. It is known that T4 DNA ligase has preferred DNA sequences for intermolecular and intramolecular DNA ligation. This ratio can be based on the molar mass ratio of the various codon-linkers or could be based on the relative efficiency of a particular codon linker to be ligated into the growing chain.
  • This relative ratio can be empirically-determined by constructing a pilot library, and sequencing several clones to determine the cloning efficiency of each codon linker.
  • a crowding agent(s) such as (10-25%) polyethylene glycol may be optionally added to the ligation mix.
  • exonuclease can be used to remove any unligated anchor or codon primer remaining in the reaction.
  • the ligated anchor- primer/codon-linker forms a molecules with both ends sealed (i.e., a single DNA strand without a free end).
  • Such a covalently-sealed molecule would be resistant to an exonuclease.
  • An example alternative means of protecting the end of the codon linker would be to incorporate a thiol-group that would render the end of the molecule similarly resistant to exonuclease digestion.
  • a restriction enzyme is used to remove the codon-linker (except for the NNN sequence) from the ligated anchor-primer/codon linker product.
  • the restriction endonulcease MIyI makes a double-strand cut 5 bases upstream (on both strands of the DNA) of its recognition site.
  • the restriction digested product can be washed away from the bound anchor-primer. The previous process can be repeated to add more codon linkers.
  • a terminal linker can be attached. This terminal linker can optionally incorporate NNN sequence at its 5' end.
  • the terminal linker could also contain a downstream primer-binding site that could be used in conjunction with the anchor primer binding site to enable one to PCR or amplify the grown chain.
  • the completed chain can be optionally separated from the substrate using various means, including a restriction enzyme, chaotropic agent, change in pH, organic solvent, heat, chemical or enzymatic decoupling.
  • the freed DNA fragment can be cloned directly into a vector, used for splice overlap extension, or amplified by one of many means, including PCR and rolling circle amplification.
  • Boder ET Midelfort KS, Wittrup KD. Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity. Proc Natl Acad Sci U S A. 2000 Sep
  • the two-hybrid system a method to identify and clone genes for proteins that interact with a protein of interest.
  • CD30 is a survival factor and a biomarker for transformed human pluripotent stem cells. Nat Biotech. 2006. 24:351-7.
  • An in vitro tumor model analysis of angiogenic factor expression after chemotherapy.
  • MNK2 human Mnk2 gene

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne l'amplification d'un anticorps sur un support solide dans une émulsion, qui produit un réactif capable de fournir un signal renforcé pouvant être utilisé pour détecter des interactions anticorps/antigène. L'amplification intervient par culture de cellules productrices d'anticorps dans des émulsions, en présence d'un support solide. Les anticorps peuvent se lier au support solide soit par une interaction antigène/anticorps, soit par une autre interaction, par exemple par l'intermédiaire d'un marqueur protéique tel que His6. La combinaison des émulsions et du support solide permet l'amplification. L'utilisation de cellules produisant des anticorps dans les émulsions permet de lier le phénotype au génotype.
PCT/US2010/033537 2009-05-04 2010-05-04 Sélection d'anticorps dans des émulsions Ceased WO2010129541A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US17507609P 2009-05-04 2009-05-04
US61/175,076 2009-05-04
US30599110P 2010-02-19 2010-02-19
US61/305,991 2010-02-19

Publications (1)

Publication Number Publication Date
WO2010129541A1 true WO2010129541A1 (fr) 2010-11-11

Family

ID=43050395

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/033537 Ceased WO2010129541A1 (fr) 2009-05-04 2010-05-04 Sélection d'anticorps dans des émulsions

Country Status (1)

Country Link
WO (1) WO2010129541A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014100419A1 (fr) 2012-12-20 2014-06-26 Axiomx, Inc. Compositions et méthodes pour identifier et isoler des fragments de liaison spécifiques de protéines de membranes cellulaires
EP4217386A4 (fr) * 2020-09-24 2025-01-15 The Broad Institute, Inc. Plateforme d'ingénierie d'anticorps acellulaires et anticorps neutralisants contre le sars-cov-2
CN119614505A (zh) * 2023-09-12 2025-03-14 珠海圣美生物诊断技术有限公司 稀有细胞捕获试剂组合及方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050042648A1 (en) * 1997-07-07 2005-02-24 Andrew Griffiths Vitro sorting method
US20060153924A1 (en) * 2003-03-31 2006-07-13 Medical Research Council Selection by compartmentalised screening
US20060154298A1 (en) * 2003-03-31 2006-07-13 Medical Research Council Method of synthesis and testing of combinatorial libraries using microcapsules
US20070009959A1 (en) * 2003-05-30 2007-01-11 Celltech R &D Limited Methods for producing antibodies
US20070077572A1 (en) * 2003-11-24 2007-04-05 Yeda Research And Development Co. Ltd. Compositions and methods for in vitro sorting of molecular and cellular libraries
US20090005264A1 (en) * 2007-03-26 2009-01-01 Codon Devices, Inc. Cell surface display, screening and production of proteins of interest

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050042648A1 (en) * 1997-07-07 2005-02-24 Andrew Griffiths Vitro sorting method
US20060153924A1 (en) * 2003-03-31 2006-07-13 Medical Research Council Selection by compartmentalised screening
US20060154298A1 (en) * 2003-03-31 2006-07-13 Medical Research Council Method of synthesis and testing of combinatorial libraries using microcapsules
US20070009959A1 (en) * 2003-05-30 2007-01-11 Celltech R &D Limited Methods for producing antibodies
US20070077572A1 (en) * 2003-11-24 2007-04-05 Yeda Research And Development Co. Ltd. Compositions and methods for in vitro sorting of molecular and cellular libraries
US20090005264A1 (en) * 2007-03-26 2009-01-01 Codon Devices, Inc. Cell surface display, screening and production of proteins of interest

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ABI-GHANEM ET AL.: "Phage display selection and characterization of single-chain recombinant antibodies against Eimeria tenella sporozoites.", VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, vol. 121, no. 1-2, 2008, pages 58 - 67 *
BERNATH ET AL.: "In vitro compartmentalization (IVC): a high-throughput screening technology using emulsions and FACS.", DISCOVERY MED., vol. 4, no. 20, 2004, pages 49 - 53 *
HOSSE ET AL.: "A new generation of protein display scaffolds for molecular recognition.", PROTEIN SCI., vol. 15, no. 1, 2006, pages 14 - 27 *
LEE ET AL.: "Bivalent antibody phage display mimics natural immunoglobulin.", J. IMMUNOL. METHODS, vol. 284, no. 1-2, 2004, pages 119 - 132 *
ROTHE ET AL.: "In vitro display technologies reveal novel biopharmaceutics.", FASEB J., vol. 20, no. 10, 2006, pages 1599 - 1610 *
SUMIDA ET AL.: "Bicistronic DNA display for in vitro selection of Fab fragments.", NUCLEIC ACIDS RES., vol. 37, no. 22, December 2009 (2009-12-01), pages 1 - 9 *
YONEZAWA ET AL.: "DNA display for in vitro selection of diverse peptide libraries.", NUCLEIC ACIDS RES., vol. 31, no. 19, 2003, pages 1 - 5 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014100419A1 (fr) 2012-12-20 2014-06-26 Axiomx, Inc. Compositions et méthodes pour identifier et isoler des fragments de liaison spécifiques de protéines de membranes cellulaires
EP2935141A4 (fr) * 2012-12-20 2016-08-10 Axiomx Inc Compositions et méthodes pour identifier et isoler des fragments de liaison spécifiques de protéines de membranes cellulaires
US10011655B2 (en) 2012-12-20 2018-07-03 Axiomx, Inc. Compositions and methods for the identification and isolation of cell-membrane protein specific binding moieties
EP3424891A1 (fr) * 2012-12-20 2019-01-09 AxioMx, Inc. Compositions et procédés d'identification et d'isolement de fractions de liaison spécifiques de la protéine de la membrane cellulaire
EP4217386A4 (fr) * 2020-09-24 2025-01-15 The Broad Institute, Inc. Plateforme d'ingénierie d'anticorps acellulaires et anticorps neutralisants contre le sars-cov-2
CN119614505A (zh) * 2023-09-12 2025-03-14 珠海圣美生物诊断技术有限公司 稀有细胞捕获试剂组合及方法
CN119614505B (zh) * 2023-09-12 2025-12-05 珠海圣美生物诊断技术有限公司 稀有细胞捕获试剂组合及方法

Similar Documents

Publication Publication Date Title
Saeed et al. Antibody engineering for pursuing a healthier future
Ding et al. Rapid isolation of antigen-specific B-cells using droplet microfluidics
EP3297661B1 (fr) Procédé d'amélioration des caractéristiques de protéines
AU2009298192B2 (en) Novel triple tag sequences and methods of use thereof
US20040048311A1 (en) Use of collections of binding sites for sample profiling and other applications
US20190002558A1 (en) Compositions and methods for the identification and isolation of cell-membrane protein specific binding moieties
US11124791B2 (en) Generating recombinant affinity reagents with arrayed targets
CN107430130A (zh) 方法
EP3223014B1 (fr) Procédé d'analyse d'interactions de serrage
WO2010129541A1 (fr) Sélection d'anticorps dans des émulsions
AU2020235455A1 (en) Method of selecting for antibodies
Buhr et al. Use of micro-emulsion technology for the directed evolution of antibodies
Jara-Acevedo et al. Methods for selecting phage display antibody libraries
US20230304190A1 (en) Methods of screening antigen-binding molecules by normalizing for the concentration of antigen-binding molecule
KR102216032B1 (ko) 합성 항체 라이브러리의 생성 방법, 상기 라이브러리 및 그 적용(들)
JP2025524400A (ja) 抗リガンドを単離する方法
Pershad et al. Drop-out phagemid vector for switching from phage displayed affinity reagents to expression formats
Schofield et al. Genetic methods of antibody generation and their use in immunohistochemistry
Kiss et al. Phage ESCape: an emulsion-based approach for the selection of recombinant phage display antibodies
US11085929B2 (en) Nanoshell-structured material as co-matrix for peptide characterization in mass spectrometry
Buckler et al. Selection and Screening of Antibody Phage Display Libraries
Buckler et al. Selection and Screening of

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10772691

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10772691

Country of ref document: EP

Kind code of ref document: A1